Frozen Section Examination of Sentinel Lymph Nodes in Breast Cancer
Frozen Section Examination of Sentinel Lymph Nodes in Breast Cancer: A Prospective Randomized Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
İzmir
-
Izmir, İzmir, Turkey (Türkiye), 35100
- SBÜ İzmir Şehir Hastanesi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients diagnosed with breast carcinoma
- No prior neoadjuvant treatment
Exclusion Criteria:
- Inability to localize the sentinel lymph node preoperatively by lymphoscintigraphy or blue dye
- Previous axillary surgery
- Recurrent breast cancer
- Patients who cannot receive radiotherapy
- Prior neoadjuvant treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Frozen Section Group
Participants undergo sentinel lymph node biopsy with intraoperative frozen section examination.
Sentinel lymph nodes are identified using blue dye and a gamma probe, and intraoperative decision-making regarding additional axillary intervention is based on frozen section results.
|
Sentinel lymph nodes are rapidly transported to pathology without formaldehyde fixation and are evaluated intraoperatively by frozen section.
|
|
Active Comparator: Routine Histopathology Group
Participants undergo sentinel lymph node biopsy without intraoperative frozen section.
Sentinel lymph nodes are identified using blue dye and a gamma probe, then processed after formaldehyde fixation with routine histopathological evaluation.
Further axillary treatment is decided according to final pathology and tumor board assessment.
|
Sentinel lymph nodes are processed after formaldehyde fixation and evaluated with routine histopathology after surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants randomized to the frozen section group and the routine histopathology group
Time Frame: From first participant enrollment until the target sample size is reached, up to 1 year
|
Count of participants randomized by sealed-envelope method to either intraoperative frozen section evaluation of sentinel lymph nodes or routine histopathological evaluation after formalin fixation.
This outcome will be reported as the total number of randomized participants until the protocol-defined target sample size for between-group comparison is reached (planned total sample size: 142 participants).
|
From first participant enrollment until the target sample size is reached, up to 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants in the routine histopathology group who require axillary lymph node dissection
Time Frame: From surgery until final histopathological evaluation and multidisciplinary treatment decision, up to 30 days
|
Percentage of participants assigned to the routine histopathology group without intraoperative frozen section who require axillary lymph node dissection based on final histopathological evaluation and multidisciplinary treatment decision.
|
From surgery until final histopathological evaluation and multidisciplinary treatment decision, up to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Orhan Ureyen, Prof. / MD, Izmir City Hospital / General Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Breast
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.